127. Frontotemporal lobar degeneration Disease details / Clinical trials / Drug dev / DR info


Clinical trials : 90 Drugs : 87 - (DrugBank : 30) / Drug target genes : 39 - Drug target pathways : 88

Drugs and their primary sponsors and trial info
(R)-[N-metil-11C1-PK11195(PK)   
   OSPEDALE S. RAFFAELE DI MILANO
      2013   -   EUCTR2012-004328-40-IT   Italy;
18-F]DPA-714   
   Erasmus Medical Center
      2020   Phase 2   EUCTR2020-002672-12-NL   Netherlands;
18F-AV-1451   
   Columbia University
      2016   Phase 2   NCT02676843   United States;
   Skåne University Hospital, Region Skåne
      2014   -   EUCTR2014-000422-38-SE   Sweden;
   VU University Medical Center
      2016   Phase 2   EUCTR2015-005604-29-NL   Netherlands;
18F-AV-45   
   Avid Radiopharmaceuticals, Inc
      2009   Phase 2   EUCTR2008-003597-18-GB   United Kingdom;
18F-FDG   
   Avid Radiopharmaceuticals
      2009   Phase 2   NCT01890343   United Kingdom;
18F-RO6958948   
   Skåne University Hospital
      2017   Phase 2   EUCTR2017-000094-36-SE   Sweden;
18F]DPA-714   
   Erasmus Medical Center
      2020   Phase 2   EUCTR2020-002672-12-NL   Netherlands;
AL001   
   Alector Inc.
      2021   Phase 3   EUCTR2019-004066-18-FR   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004066-18-SE   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004066-18-PT   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004066-18-NL   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004066-18-IT   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004066-18-GB   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004066-18-ES   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004066-18-DE   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004066-18-BE   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 2   NCT03987295   Canada;Germany;Italy;Netherlands;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000138-20-NL   Canada;Germany;Italy;Netherlands;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000138-20-IT   Canada;Germany;Italy;Netherlands;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000138-20-GB   Canada;Germany;Italy;Netherlands;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000138-20-DE   Canada;Germany;Italy;Netherlands;United Kingdom;United States;
      2018   Phase 1   NCT03636204   Canada;Netherlands;United Kingdom;United States;
AV1451 Tau   
   Mayo Clinic
      2020   -   NCT04680130   United States;
Amantadine   
   Johns Hopkins University
      2005   Phase 4   NCT00127114   United States;
Amyvid   
   IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli
      2014   -   EUCTR2014-001315-40-IT   Italy;
BIIB092   
   University of California, San Francisco
      2018   Phase 1   NCT03658135   United States;
Blood sample   
   University Hospital, Lille
      2021   -   NCT05288842   France;
Brain PET scan   
   Avid Radiopharmaceuticals
      2017   Phase 1   NCT03040713   United States;
C-11 PiB   
   Mayo Clinic
      2020   -   NCT04680130   United States;
      2010   Phase 1   NCT01623284   United States;
Citalopram   
   Sunnybrook Health Sciences Centre
      2006   Phase 4   NCT00376051   Canada;
DNL593   
   Denali Therapeutics Inc.
      2022   Phase 1/Phase 2   NCT05262023   United Kingdom;
Davunetide (AL-108, NAP)   
   University of California, San Francisco
      2010   Phase 1   NCT01056965   United States;
Donepezil   
   National Hospital Organization Kikuchi Hospital
      2008   -   JPRN-UMIN000003239   Japan;
EVP-0334   
   FORUM Pharmaceuticals Inc.
      2015   Phase 2;Phase 3   EUCTR2014-001489-85-GB   Belgium;France;Italy;Netherlands;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-001489-85-BE   Belgium;France;Italy;Netherlands;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001489-85-NL   Belgium;France;Italy;Netherlands;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001489-85-IT   Belgium;France;Italy;Netherlands;United Kingdom;United States;
F 18 T807   
   Tammie L. S. Benzinger, MD, PhD
      2017   Phase 2   NCT02707978   United States;
F-18   
   Chang Gung Memorial Hospital
      2018   Early Phase 1   NCT03625128   Taiwan;
F-18 FDG   
   Mayo Clinic
      2010   Phase 1   NCT01623284   United States;
      2008   Phase 4   NCT00950430   United States;
FRM-0334   
   FORUM Pharmaceuticals Inc
      2014   Phase 2   NCT02149160   Belgium;France;Italy;Netherlands;United Kingdom;United States;
   FORUM Pharmaceuticals Inc.
      2015   Phase 2;Phase 3   EUCTR2014-001489-85-GB   Belgium;France;Italy;Netherlands;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-001489-85-BE   Belgium;France;Italy;Netherlands;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001489-85-NL   Belgium;France;Italy;Netherlands;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001489-85-IT   Belgium;France;Italy;Netherlands;United Kingdom;United States;
Ferulic acid   
   Shimane University Hospital
      2010   -   JPRN-UMIN000003683   Japan;
Florbetapir (18F)   
   IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli
      2014   -   EUCTR2014-001315-40-IT   Italy;
Florbetapir 18F   
   Avid Radiopharmaceuticals
      2009   Phase 2   NCT01890343   United Kingdom;
Florbetapir 18F Injection   
   Avid Radiopharmaceuticals, Inc
      2009   Phase 2   EUCTR2008-003597-18-GB   United Kingdom;
Flortaucipir F18   
   Avid Radiopharmaceuticals
      2017   Phase 1   NCT03040713   United States;
Flutemetamol F18   
   Skane University Hospital
      2017   -   NCT03174938   Sweden;
Galantamine hydrobromide   
   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
      2003   Phase 2   NCT00416169   -
Histone Deacetylase Inhibitor   
   FORUM Pharmaceuticals Inc.
      2015   Phase 2;Phase 3   EUCTR2014-001489-85-GB   Belgium;France;Italy;Netherlands;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-001489-85-BE   Belgium;France;Italy;Netherlands;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001489-85-NL   Belgium;France;Italy;Netherlands;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001489-85-IT   Belgium;France;Italy;Netherlands;United Kingdom;United States;
Intranasal oxytocin   
   Lawson Health Research Institute
      2013   Phase 2   NCT01937013   Canada;
      2009   -   NCT01002300   Canada;
LMTM   
   TauRx Therapeutics Ltd
      2014   Phase 3   NCT02245568   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Finland;France;Germany;Italy;Korea, Republic of;Malaysia;Netherlands;Poland;Romania;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
LMTM/TRx0237   
   TauRx Therapeutics Ltd
      2016   Phase 3   EUCTR2014-002013-37-NL   Australia;Belgium;Bulgaria;Canada;Croatia;Finland;France;Germany;Korea, Republic of;Malaysia;Netherlands;Romania;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002013-37-HR   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Finland;France;Germany;Korea, Republic of;Malaysia;Netherlands;Romania;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002013-37-FI   Australia;Belgium;Canada;Croatia;Finland;France;Germany;Korea, Republic of;Malaysia;Netherlands;Romania;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002013-37-ES   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Finland;France;Germany;Italy;Korea, Republic of;Malaysia;Netherlands;Poland;Romania;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002013-37-BE   Australia;Belgium;Bulgaria;Canada;Croatia;Finland;France;Germany;Italy;Korea, Republic of;Malaysia;Netherlands;Poland;Romania;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-002013-37-GB   Australia;Belgium;Bulgaria;Canada;Croatia;Finland;France;Germany;Korea, Republic of;Malaysia;Netherlands;Romania;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005529-34-PL   Australia;Canada;Croatia;Finland;Germany;Italy;Netherlands;Poland;Romania;Singapore;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005529-34-IT   Australia;Canada;Croatia;Finland;Germany;Italy;Netherlands;Poland;Singapore;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005529-34-HR   Australia;Canada;Croatia;Finland;Germany;Italy;Netherlands;Poland;Romania;Singapore;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005529-34-FI   Australia;Canada;Croatia;Finland;Germany;Italy;Netherlands;Poland;Singapore;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005529-34-ES   Australia;Canada;Croatia;Finland;Germany;Italy;Netherlands;Poland;Singapore;Spain;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-005529-34-NL   Australia;Canada;Croatia;Finland;Germany;Italy;Netherlands;Poland;Singapore;Spain;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-005529-34-GB   Australia;Canada;Croatia;Finland;Germany;Italy;Netherlands;Poland;Romania;Singapore;Spain;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-005529-34-DE   Australia;Canada;Croatia;Finland;Germany;Italy;Netherlands;Poland;Romania;Singapore;Spain;United Kingdom;United States;
Latozinemab   
   Alector Inc.
      2019   Phase 2   EUCTR2019-000138-20-DE   Canada;Germany;Italy;Netherlands;United Kingdom;United States;
Leucine   
   Washington University School of Medicine
      2017   -   NCT03545126   United States;
Leuco-methylthioninium bis(hydromethanesulfonate)   
   TauRx Therapeutics Ltd
      2016   Phase 3   EUCTR2014-002013-37-NL   Australia;Belgium;Bulgaria;Canada;Croatia;Finland;France;Germany;Korea, Republic of;Malaysia;Netherlands;Romania;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002013-37-HR   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Finland;France;Germany;Korea, Republic of;Malaysia;Netherlands;Romania;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002013-37-FI   Australia;Belgium;Canada;Croatia;Finland;France;Germany;Korea, Republic of;Malaysia;Netherlands;Romania;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002013-37-ES   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Finland;France;Germany;Italy;Korea, Republic of;Malaysia;Netherlands;Poland;Romania;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002013-37-BE   Australia;Belgium;Bulgaria;Canada;Croatia;Finland;France;Germany;Italy;Korea, Republic of;Malaysia;Netherlands;Poland;Romania;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-002013-37-GB   Australia;Belgium;Bulgaria;Canada;Croatia;Finland;France;Germany;Korea, Republic of;Malaysia;Netherlands;Romania;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005529-34-PL   Australia;Canada;Croatia;Finland;Germany;Italy;Netherlands;Poland;Romania;Singapore;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005529-34-IT   Australia;Canada;Croatia;Finland;Germany;Italy;Netherlands;Poland;Singapore;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005529-34-HR   Australia;Canada;Croatia;Finland;Germany;Italy;Netherlands;Poland;Romania;Singapore;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005529-34-FI   Australia;Canada;Croatia;Finland;Germany;Italy;Netherlands;Poland;Singapore;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005529-34-ES   Australia;Canada;Croatia;Finland;Germany;Italy;Netherlands;Poland;Singapore;Spain;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-005529-34-NL   Australia;Canada;Croatia;Finland;Germany;Italy;Netherlands;Poland;Singapore;Spain;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-005529-34-GB   Australia;Canada;Croatia;Finland;Germany;Italy;Netherlands;Poland;Romania;Singapore;Spain;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-005529-34-DE   Australia;Canada;Croatia;Finland;Germany;Italy;Netherlands;Poland;Romania;Singapore;Spain;United Kingdom;United States;
Lumbar puncture   
   University Hospital, Lille
      2021   -   NCT05288842   France;
MTC TRx0014-001 capsules   
   TauRx Therapeutics PTE Ltd
      2006   Phase 2   EUCTR2005-005915-13-GB   United Kingdom;
Memantine   
   Nantes University Hospital
      2005   Phase 2   NCT00200538   France;
   University of California, San Francisco
      2007   Phase 4   NCT00545974   United States;
      2004   Phase 4   NCT00187525   -
Memantine hydrochloride   
   Tiffany Chow, MD
      2007   Phase 3   NCT00594737   Canada;
Metformin   
   University of Florida
      2020   Phase 2   NCT04220021   United States;
Methylprednisolone   
   Prevail Therapeutics
      2020   Phase 1/Phase 2   NCT04408625   Australia;Spain;United States;
Methylthioninium chloride   
   TauRx Therapeutics PTE Ltd
      2006   Phase 2   EUCTR2005-005915-13-GB   United Kingdom;
N,N,N',N'-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate)   
   TauRx Therapeutics Ltd
      2016   Phase 3   EUCTR2014-002013-37-NL   Australia;Belgium;Bulgaria;Canada;Croatia;Finland;France;Germany;Korea, Republic of;Malaysia;Netherlands;Romania;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002013-37-HR   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Finland;France;Germany;Korea, Republic of;Malaysia;Netherlands;Romania;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002013-37-FI   Australia;Belgium;Canada;Croatia;Finland;France;Germany;Korea, Republic of;Malaysia;Netherlands;Romania;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002013-37-ES   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Finland;France;Germany;Italy;Korea, Republic of;Malaysia;Netherlands;Poland;Romania;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002013-37-BE   Australia;Belgium;Bulgaria;Canada;Croatia;Finland;France;Germany;Italy;Korea, Republic of;Malaysia;Netherlands;Poland;Romania;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-002013-37-GB   Australia;Belgium;Bulgaria;Canada;Croatia;Finland;France;Germany;Korea, Republic of;Malaysia;Netherlands;Romania;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States;
N,N,N?,N?-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate)   
   TauRx Therapeutics Ltd
      2014   Phase 3   EUCTR2011-005529-34-ES   Australia;Canada;Croatia;Finland;Germany;Italy;Netherlands;Poland;Singapore;Spain;United Kingdom;United States;
N,N,N’,N’-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate)   
   TauRx Therapeutics Ltd
      2014   Phase 3   EUCTR2011-005529-34-PL   Australia;Canada;Croatia;Finland;Germany;Italy;Netherlands;Poland;Romania;Singapore;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005529-34-IT   Australia;Canada;Croatia;Finland;Germany;Italy;Netherlands;Poland;Singapore;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005529-34-HR   Australia;Canada;Croatia;Finland;Germany;Italy;Netherlands;Poland;Romania;Singapore;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005529-34-FI   Australia;Canada;Croatia;Finland;Germany;Italy;Netherlands;Poland;Singapore;Spain;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-005529-34-NL   Australia;Canada;Croatia;Finland;Germany;Italy;Netherlands;Poland;Singapore;Spain;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-005529-34-GB   Australia;Canada;Croatia;Finland;Germany;Italy;Netherlands;Poland;Romania;Singapore;Spain;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-005529-34-DE   Australia;Canada;Croatia;Finland;Germany;Italy;Netherlands;Poland;Romania;Singapore;Spain;United Kingdom;United States;
Neurohormonal mechanisms   
   Institut National de la Santé Et de la Recherche Médicale, France
      2017   -   NCT03272230   France;
Novolin-R insulin   
   HealthPartners Institute
      2019   Phase 2   NCT04115384   United States;
Open label - AL001   
   Alector Inc.
      2020   Phase 3   NCT04374136   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
Oxytocin   
   Lawson Health Research Institute
      2011   Phase 1   NCT01386333   Canada;
PBFT02   
   Passage Bio, Inc.
      2021   Phase 1/Phase 2   NCT04747431   Brazil;Canada;Italy;Portugal;United Kingdom;United States;
PEA-LUT   
   I.R.C.C.S. Fondazione Santa Lucia
      2019   -   NCT04489017   Italy;
PR006   
   Prevail Therapeutics
      2020   Phase 1/Phase 2   NCT04408625   Australia;Spain;United States;
Pittsburgh Compound B (C-11 PiB)   
   Mayo Clinic
      2008   Phase 4   NCT00950430   United States;
Prednisone   
   Prevail Therapeutics
      2020   Phase 1/Phase 2   NCT04408625   Australia;Spain;United States;
Rituximab   
   Prevail Therapeutics
      2020   Phase 1/Phase 2   NCT04408625   Australia;Spain;United States;
Rotigotine 4Mg/24Hrs Patch   
   I.R.C.C.S. Fondazione Santa Lucia
      2021   Phase 2   NCT04937452   Italy;
Rotigotine 6Mg/24Hrs Patch   
   I.R.C.C.S. Fondazione Santa Lucia
      2021   Phase 2   NCT04937452   Italy;
Saline Nasal Mist   
   Lawson Health Research Institute
      2013   Phase 2   NCT01937013   Canada;
      2011   Phase 1   NCT01386333   Canada;
Sirolimus   
   Prevail Therapeutics
      2020   Phase 1/Phase 2   NCT04408625   Australia;Spain;United States;
Synthetic stereopure antisense oligonucleotide targeting human C9orf72 hexanucleotide repeat-containing mRNA transcripts   
   Wave Life Sciences UK Limited
      2022   Phase 1;Phase 2   EUCTR2020-005193-94-SE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;New Zealand;Sweden;United Kingdom;United States;
      2022   Phase 1;Phase 2   EUCTR2020-005193-94-BE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;New Zealand;Sweden;United Kingdom;United States;
Syntocinon   
   Lawson Health Research Institute
      2018   Phase 2   NCT03260920   Canada;United States;
T807   
   VU University Medical Center
      2016   Phase 2   EUCTR2015-005604-29-NL   Netherlands;
TPN-101   
   Transposon Therapeutics, Inc
      2022   Phase 2   EUCTR2021-002251-11-ES   Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
TPN-101, 400 mg/day   
   Transposon Therapeutics, Inc.
      2021   Phase 2   NCT04993755   France;United States;
TRx0237   
   TauRx Therapeutics Ltd
      2013   Phase 3   NCT01626378   Argentina;Australia;Bulgaria;Canada;Croatia;Finland;Germany;Italy;Netherlands;Poland;Romania;Singapore;Spain;United Kingdom;United States;
Tau (18-F-AV-1451)   
   Mayo Clinic
      2008   Phase 4   NCT00950430   United States;
Tolcapone   
   Columbia University
      2011   Phase 2   NCT00604591   United States;
Verdiperstat   
   Peter Ljubenkov, MD
      2022   Phase 1   NCT05184569   -
Vizamyl (flutemetamol(F-18))   
   Skåne University Hospital
      2017   Phase 2   EUCTR2017-000094-36-SE   Sweden;
WVE-004   
   Wave Life Sciences Ltd.
      2021   Phase 1/Phase 2   NCT04931862   Australia;Canada;Ireland;Netherlands;United Kingdom;
   Wave Life Sciences UK Limited
      2022   Phase 1;Phase 2   EUCTR2020-005193-94-SE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;New Zealand;Sweden;United Kingdom;United States;
      2022   Phase 1;Phase 2   EUCTR2020-005193-94-BE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;New Zealand;Sweden;United Kingdom;United States;
[18F]PI-2620   
   Asan Medical Center
      2018   Early Phase 1   NCT03510572   Korea, Republic of;